APO RESEARCH · REPORT
Vaccine Adjuvants
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
Product & engineering
Understand the product.
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
Selected research
Industry Research
Vaccine Adjuvants Industry Research Report 2026
Market perspective
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
The top 5 global manufacturers of vaccine adjuvants are GSK, CSL Limited, Croda, SEPPIC, Novavax, which have a combined market share of about 55 percent. North America is the largest market, with a share about 38%, followed by Europe and Asia Pacific with the share about 27% and 22%.
Report Scope
Read the full market overview
This report quantifies the global Vaccine Adjuvants market in terms of revenue (US$ million) and, where applicable, sales volume (MT), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/MT) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vaccine Adjuvants Market by Company
GSK
CSL Limited
Croda
SEPPIC
Novavax
SPI Pharma
Phibro
SDA BIO
Invivogen
Tj Kaiwei
OZ Biosciences
Brenntag Biosector
MVP Laboratories
Zhuoyue
Aphios
Vaccine Adjuvants Segment by Type
Aluminum Adjuvant
Emulsions Adjuvant
Others
Vaccine Adjuvants Segment by Application
Human Vaccine
Veterinary Vaccine
Vaccine Adjuvants Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Adjuvants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vaccine Adjuvants manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vaccine Adjuvants by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vaccine Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Aluminum Adjuvant
- Emulsions Adjuvant
- Others
Applications
- Human Vaccine
- Veterinary Vaccine
Companies covered
- GSK
- CSL Limited
- Croda
- SEPPIC
- Novavax
- SPI Pharma
- Phibro
- SDA BIO
- Invivogen
- Tj Kaiwei
- OZ Biosciences
- Brenntag Biosector
- MVP Laboratories
- Zhuoyue
- Aphios
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vaccine Adjuvants Market Size (2021-2032)
- 2.2.2 Global Vaccine Adjuvants Sales (2021-2032)
- 2.2.3 Global Vaccine Adjuvants Market Average Price (2021-2032)
- 2.3 Vaccine Adjuvants by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Aluminum Adjuvant
- 2.3.3 Emulsions Adjuvant
- 2.3.4 Others
- 2.4 Vaccine Adjuvants by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Human Vaccine
- 2.4.3 Veterinary Vaccine
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vaccine Adjuvants Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vaccine Adjuvants Sales (MT) of Manufacturers (2021-2026)
- 3.3 Global Vaccine Adjuvants Revenue of Manufacturers (2021-2026)
- 3.4 Global Vaccine Adjuvants Average Price by Manufacturers (2021-2026)
- 3.5 Global Vaccine Adjuvants Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vaccine Adjuvants, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vaccine Adjuvants, Product Type & Application
- 3.8 Global Manufacturers of Vaccine Adjuvants, Established Date
- 3.9 Global Vaccine Adjuvants Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Vaccine Adjuvants Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 CSL Limited
- 4.2.1 CSL Limited Company Information
- 4.2.2 CSL Limited Business Overview
- 4.2.3 CSL Limited Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSL Limited Vaccine Adjuvants Product Portfolio
- 4.2.5 CSL Limited Recent Developments
- 4.3 Croda
- 4.3.1 Croda Company Information
- 4.3.2 Croda Business Overview
- 4.3.3 Croda Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Croda Vaccine Adjuvants Product Portfolio
- 4.3.5 Croda Recent Developments
- 4.4 SEPPIC
- 4.4.1 SEPPIC Company Information
- 4.4.2 SEPPIC Business Overview
- 4.4.3 SEPPIC Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 SEPPIC Vaccine Adjuvants Product Portfolio
- 4.4.5 SEPPIC Recent Developments
- 4.5 Novavax
- 4.5.1 Novavax Company Information
- 4.5.2 Novavax Business Overview
- 4.5.3 Novavax Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novavax Vaccine Adjuvants Product Portfolio
- 4.5.5 Novavax Recent Developments
- 4.6 SPI Pharma
- 4.6.1 SPI Pharma Company Information
- 4.6.2 SPI Pharma Business Overview
- 4.6.3 SPI Pharma Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 SPI Pharma Vaccine Adjuvants Product Portfolio
- 4.6.5 SPI Pharma Recent Developments
- 4.7 Phibro
- 4.7.1 Phibro Company Information
- 4.7.2 Phibro Business Overview
- 4.7.3 Phibro Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Phibro Vaccine Adjuvants Product Portfolio
- 4.7.5 Phibro Recent Developments
- 4.8 SDA BIO
- 4.8.1 SDA BIO Company Information
- 4.8.2 SDA BIO Business Overview
- 4.8.3 SDA BIO Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 SDA BIO Vaccine Adjuvants Product Portfolio
- 4.8.5 SDA BIO Recent Developments
- 4.9 Invivogen
- 4.9.1 Invivogen Company Information
- 4.9.2 Invivogen Business Overview
- 4.9.3 Invivogen Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Invivogen Vaccine Adjuvants Product Portfolio
- 4.9.5 Invivogen Recent Developments
- 4.10 Tj Kaiwei
- 4.10.1 Tj Kaiwei Company Information
- 4.10.2 Tj Kaiwei Business Overview
- 4.10.3 Tj Kaiwei Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Tj Kaiwei Vaccine Adjuvants Product Portfolio
- 4.10.5 Tj Kaiwei Recent Developments
- 4.11 OZ Biosciences
- 4.11.1 OZ Biosciences Company Information
- 4.11.2 OZ Biosciences Business Overview
- 4.11.3 OZ Biosciences Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 OZ Biosciences Vaccine Adjuvants Product Portfolio
- 4.11.5 OZ Biosciences Recent Developments
- 4.12 Brenntag Biosector
- 4.12.1 Brenntag Biosector Company Information
- 4.12.2 Brenntag Biosector Business Overview
- 4.12.3 Brenntag Biosector Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Brenntag Biosector Vaccine Adjuvants Product Portfolio
- 4.12.5 Brenntag Biosector Recent Developments
- 4.13 MVP Laboratories
- 4.13.1 MVP Laboratories Company Information
- 4.13.2 MVP Laboratories Business Overview
- 4.13.3 MVP Laboratories Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 MVP Laboratories Vaccine Adjuvants Product Portfolio
- 4.13.5 MVP Laboratories Recent Developments
- 4.14 Zhuoyue
- 4.14.1 Zhuoyue Company Information
- 4.14.2 Zhuoyue Business Overview
- 4.14.3 Zhuoyue Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Zhuoyue Vaccine Adjuvants Product Portfolio
- 4.14.5 Zhuoyue Recent Developments
- 4.15 Aphios
- 4.15.1 Aphios Company Information
- 4.15.2 Aphios Business Overview
- 4.15.3 Aphios Vaccine Adjuvants Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Aphios Vaccine Adjuvants Product Portfolio
- 4.15.5 Aphios Recent Developments
5 Global Vaccine Adjuvants Market Scenario by Region
- 5.1 Global Vaccine Adjuvants Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vaccine Adjuvants Sales by Region: 2021-2032
- 5.2.1 Global Vaccine Adjuvants Sales by Region: 2021-2026
- 5.2.2 Global Vaccine Adjuvants Sales by Region: 2027-2032
- 5.3 Global Vaccine Adjuvants Revenue by Region: 2021-2032
- 5.3.1 Global Vaccine Adjuvants Revenue by Region: 2021-2026
- 5.3.2 Global Vaccine Adjuvants Revenue by Region: 2027-2032
- 5.4 North America Vaccine Adjuvants Market Facts & Figures by Country
- 5.4.1 North America Vaccine Adjuvants Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vaccine Adjuvants Sales by Country (2021-2032)
- 5.4.3 North America Vaccine Adjuvants Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Vaccine Adjuvants Market Facts & Figures by Country
- 5.5.1 Europe Vaccine Adjuvants Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vaccine Adjuvants Sales by Country (2021-2032)
- 5.5.3 Europe Vaccine Adjuvants Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Vaccine Adjuvants Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vaccine Adjuvants Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vaccine Adjuvants Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vaccine Adjuvants Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vaccine Adjuvants Market Facts & Figures by Country
- 5.7.1 South America Vaccine Adjuvants Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vaccine Adjuvants Sales by Country (2021-2032)
- 5.7.3 South America Vaccine Adjuvants Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Vaccine Adjuvants Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vaccine Adjuvants Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vaccine Adjuvants Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vaccine Adjuvants Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Vaccine Adjuvants Sales by Type (2021-2032)
- 6.1.1 Global Vaccine Adjuvants Sales by Type (2021-2032) & (MT)
- 6.1.2 Global Vaccine Adjuvants Sales Market Share by Type (2021-2032)
- 6.2 Global Vaccine Adjuvants Revenue by Type (2021-2032)
- 6.2.1 Global Vaccine Adjuvants Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vaccine Adjuvants Revenue Market Share by Type (2021-2032)
- 6.3 Global Vaccine Adjuvants Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vaccine Adjuvants Sales by Application (2021-2032)
- 7.1.1 Global Vaccine Adjuvants Sales by Application (2021-2032) & (MT)
- 7.1.2 Global Vaccine Adjuvants Sales Market Share by Application (2021-2032)
- 7.2 Global Vaccine Adjuvants Revenue by Application (2021-2032)
- 7.2.1 Global Vaccine Adjuvants Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vaccine Adjuvants Revenue Market Share by Application (2021-2032)
- 7.3 Global Vaccine Adjuvants Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vaccine Adjuvants Value Chain Analysis
- 8.1.1 Vaccine Adjuvants Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vaccine Adjuvants Production Mode & Process
- 8.2 Vaccine Adjuvants Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vaccine Adjuvants Distributors
- 8.2.3 Vaccine Adjuvants Customers
9 Global Vaccine Adjuvants Analyzing Market Dynamics
- 9.1 Vaccine Adjuvants Industry Trends
- 9.2 Vaccine Adjuvants Industry Drivers
- 9.3 Vaccine Adjuvants Industry Opportunities and Challenges
- 9.4 Vaccine Adjuvants Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst